FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130654464> ?p ?o ?g. }

• W2130654464 abstract "Hepatitis C virus (HCV) infection is common in chronic kidney disease (CKD) patients on dialysis, causes chronic liver disease, increases mortality and impacts kidney transplant outcomes. Sustained response to the preferred treatment with standard or pegylated (PEG) interferon is seen in 39% with side effects necessitating treatment discontinuation in 20%. We collated evidence for treatment response and harms of interventions for HCV infection in dialysis.We aimed to look at the benefits and harms of various interventions for HCV infection in CKD patients on HD or peritoneal dialysis, specifically on mortality, disease relapse, response to treatment, treatment discontinuation, time to recovery, quality of life, cost effectiveness,adverse effects, and other outcomes. We aimed to study comparisons of available interventions with a placebo or control group, combinations of interventions with placebo or control group, interventions with each other singly and in combination, available standard interventions with newer treatment modalities.We searched Cochrane Kidney and Transplant's Specialised Register to 24 March 2015 through contact with the Trials' Search Co-ordinator. We also checked references of reviews, studies and contacted study authors to identify additional studies.Randomised controlled trials (RCTs), quasi-RCTs, first period of randomised cross-over studies on interventions for HCV in CKD on dialysis were considered.We used standard methodological procedures expected by the Cochrane Collaboration and also collected adverse effects data listed in included RCTs.Ten RCTs (361 participants) met our inclusion criteria. Five RCTs (152 participants, 134 analysed) with low to moderate quality of evidence compared standard recombinant interferon with placebo or control. There was no significant difference for mortality (5 studies (134 participants): RR 0.89, 95% CI 0.06 to 13.23), relapses (1 study (36 participants): RR 0.72, 95% CI 0.28 to 1.88), sustained virological response (4 studies (98 participants): RR 3.25, 95% CI 0.81 to 13.07), treatment discontinuation (4 studies (116 participants): RR 4.59, 95% CI 0.49 to 42.69) and number with adverse events (5 studies (143 participants): RR 3.56, 95% CI 0.98 to 13.01). End of treatment response was significantly more for standard interferon (5 studies (132 participants): RR 8.62, 95% CI 3.03 to 24.55). There was overall low to unclear risk of bias and no significant heterogeneity.One RCT (50 participants) with moderate quality of evidence compared PEG interferon and standard interferon. There was no significant difference in mortality (RR 0.33, 95% CI 0.01 to 7.81), relapses (RR 0.72, 95% CI 0.41 to 1.25), sustained virological response (RR 2.40, 95% CI 0.99 to 5.81), treatment discontinuation (RR 0.11, 95% CI 0.01 to 1.96) and number with major adverse events (RR 0.11, 95% CI 0.01 to 1.96). End of treatment response was significantly more for PEG interferon (RR 1.53, 95% CI 1.09 to 2.15). There was overall low risk of bias.Two RCTs (97 participants) with moderate quality of evidence compared two doses of two different preparations of PEG interferon. Subgroup analysis comparing high and low doses of PEG interferon alpha-2a (135 µg/week versus 90 µg/week) and PEG interferon alpha-2b (1 µg/kg versus 0.5 µg/kg body weight/week) found no significant difference in mortality (2 studies (97 participants): RR 4.30, 95% CI 0.76 to 24.33), relapses (1 study (81 participants): RR 1.11, 95% CI 0.45 to 2.77), end of treatment response (2 studies (97 participants): RR 1.42, 95% CI 0.51 to 3.90), sustained virological response (2 studies (97 participants): RR 1.19, 95% CI 0.68 to 2.07), treatment discontinuation (2 studies (97 participants): RR 1.20, 95% CI 0.63 to 2.28), patients with adverse events (2 studies (97 participants): RR 1.05, 95% CI 0.61 to 1.83) or serious adverse events (2 studies (97 participants): RR 1.24, 95% CI 0.72 to 2.14). Both had overall low risk of bias and no significant subgroup differences.Two RCTs (62 participants) with moderate quality of evidence compared standard or PEG interferon alone or in combination with ribavirin. The only reported outcome in both was treatment discontinuation which was significantly more with ribavirin in the one study (RR 0.34, 95% CI 0.14 to 0.84) and pooled 7/10 in the second.No RCTs had data on time to recovery, cost-effectiveness, quality of life, and other outcomes and in peritoneal dialysis.Our review demonstrated that in CKD patients on haemodialysis with HCV infection treatment with standard interferon brings about an end of treatment but not a sustained virological response and is relatively well tolerated. PEG interferon is more effective than standard interferon for end of treatment response but not for sustained response; both were equally tolerated. Increasing doses of PEG interferon did not improve responses but high and low doses are equally tolerated. Addition of ribavirin results in more treatment discontinuation." @default.
• W2130654464 created "2016-06-24" @default.
• W2130654464 creator A5005812071 @default.
• W2130654464 creator A5014853050 @default.
• W2130654464 creator A5026030539 @default.
• W2130654464 creator A5035298080 @default.
• W2130654464 creator A5046115373 @default.
• W2130654464 date "2015-08-19" @default.
• W2130654464 modified "2023-10-10" @default.
• W2130654464 title "Interventions for dialysis patients with hepatitis C virus (HCV) infection" @default.
• W2130654464 cites W1502204677 @default.
• W2130654464 cites W1505651735 @default.
• W2130654464 cites W168801316 @default.
• W2130654464 cites W1963895119 @default.
• W2130654464 cites W1968013127 @default.
• W2130654464 cites W1970062940 @default.
• W2130654464 cites W1975765367 @default.
• W2130654464 cites W1977897254 @default.
• W2130654464 cites W1991062024 @default.
• W2130654464 cites W1991815197 @default.
• W2130654464 cites W1992766050 @default.
• W2130654464 cites W1993960896 @default.
• W2130654464 cites W1997213606 @default.
• W2130654464 cites W1998437853 @default.
• W2130654464 cites W2006309458 @default.
• W2130654464 cites W2009482238 @default.
• W2130654464 cites W2011500811 @default.
• W2130654464 cites W2022060971 @default.
• W2130654464 cites W2022561069 @default.
• W2130654464 cites W2025661983 @default.
• W2130654464 cites W2028489782 @default.
• W2130654464 cites W2029215231 @default.
• W2130654464 cites W2032917414 @default.
• W2130654464 cites W2043519223 @default.
• W2130654464 cites W2047329659 @default.
• W2130654464 cites W2058072615 @default.
• W2130654464 cites W2058720438 @default.
• W2130654464 cites W2060229598 @default.
• W2130654464 cites W2061992263 @default.
• W2130654464 cites W2066145644 @default.
• W2130654464 cites W2071210454 @default.
• W2130654464 cites W2072330941 @default.
• W2130654464 cites W2077220893 @default.
• W2130654464 cites W2077439054 @default.
• W2130654464 cites W2082576838 @default.
• W2130654464 cites W2098923148 @default.
• W2130654464 cites W2106892691 @default.
• W2130654464 cites W2111918769 @default.
• W2130654464 cites W2118268231 @default.
• W2130654464 cites W2119806249 @default.
• W2130654464 cites W2125435699 @default.
• W2130654464 cites W2130654464 @default.
• W2130654464 cites W2151471855 @default.
• W2130654464 cites W2152611051 @default.
• W2130654464 cites W2153349186 @default.
• W2130654464 cites W2161271191 @default.
• W2130654464 cites W2162456167 @default.
• W2130654464 cites W2164626021 @default.
• W2130654464 cites W2235207261 @default.
• W2130654464 cites W2325033177 @default.
• W2130654464 cites W2405672004 @default.
• W2130654464 cites W2407523321 @default.
• W2130654464 cites W2409887450 @default.
• W2130654464 cites W2438205568 @default.
• W2130654464 cites W2466462007 @default.
• W2130654464 cites W2588681363 @default.
• W2130654464 cites W2607031541 @default.
• W2130654464 cites W2978038497 @default.
• W2130654464 cites W4243816464 @default.
• W2130654464 doi "https://doi.org/10.1002/14651858.cd007003.pub2" @default.
• W2130654464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26287983" @default.
• W2130654464 hasPublicationYear "2015" @default.
• W2130654464 type Work @default.
• W2130654464 sameAs 2130654464 @default.
• W2130654464 citedByCount "9" @default.
• W2130654464 countsByYear W21306544642015 @default.
• W2130654464 countsByYear W21306544642016 @default.
• W2130654464 countsByYear W21306544642017 @default.
• W2130654464 countsByYear W21306544642019 @default.
• W2130654464 countsByYear W21306544642020 @default.
• W2130654464 countsByYear W21306544642023 @default.
• W2130654464 crossrefType "journal-article" @default.
• W2130654464 hasAuthorship W2130654464A5005812071 @default.
• W2130654464 hasAuthorship W2130654464A5014853050 @default.
• W2130654464 hasAuthorship W2130654464A5026030539 @default.
• W2130654464 hasAuthorship W2130654464A5035298080 @default.
• W2130654464 hasAuthorship W2130654464A5046115373 @default.
• W2130654464 hasBestOaLocation W21306544641 @default.
• W2130654464 hasConcept C118552586 @default.
• W2130654464 hasConcept C126322002 @default.
• W2130654464 hasConcept C142724271 @default.
• W2130654464 hasConcept C168563851 @default.
• W2130654464 hasConcept C177713679 @default.
• W2130654464 hasConcept C197934379 @default.
• W2130654464 hasConcept C203014093 @default.
• W2130654464 hasConcept C204787440 @default.
• W2130654464 hasConcept C2522874641 @default.
• W2130654464 hasConcept C27081682 @default.
• W2130654464 hasConcept C27415008 @default.
• W2130654464 hasConcept C2776408679 @default.

• next